Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group study

被引：2
|
作者：
Lee, C. [1 ]
Tang, Y. [1 ]
Schroeder, C. [1 ]
Zhang, J. [1 ]
Nguyen-Cleary, T. [1 ]
Mullin, S. [1 ]
Ma, M. [1 ]
Lyon, N. [1 ]
Grundy, J. [1 ]
机构：
[1] Arena Pharmaceut Inc, San Diego, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.415
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P291
引用
收藏
页码：S321 / S322
页数：4
相关论文
共 50 条
  • [1] Pharmacokinetics (PK), Safety, and Tolerability of Etrasimod (APD334) in Participants With Mild, Moderate, or Severe Hepatic Impairment: A Single-Dose, Open-Label, Parallel-Group Study
    Lee, Caroline
    Tang, Yong
    Schroeder, Cassandra
    Zhang, Jinkun
    Nguyen-Cleary, Thai
    Ma, Michael
    Lyon, Naomi
    Grundy, John S.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S327 - S328
  • [2] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Bola Tayo
    Lesley Taylor
    Farhad Sahebkar
    Gilmour Morrison
    [J]. Clinical Pharmacokinetics, 2020, 59 : 747 - 755
  • [3] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Tayo, Bola
    Taylor, Lesley
    Sahebkar, Farhad
    Morrison, Gilmour
    [J]. CLINICAL PHARMACOKINETICS, 2020, 59 (06) : 747 - 755
  • [4] A Phase 1, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics and Safety of Cannabidiol (CBD) in Subjects With Mild to Severe Hepatic Impairment
    Taylor, Lesley
    Crockett, Julie
    Tayo, Bola
    Morrison, Gilmour
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (08): : 1110 - 1119
  • [5] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
    Gardin, Anne
    Dodman, Angela
    Kalluri, Sampath
    Neelakantham, Srikanth
    Tan, Xuemei
    Legangneux, Eric
    Shakeri-Nejad, Kasra
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 54 - 65
  • [6] Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study
    David, Olivier J.
    Pryce, Maxwell
    Meiser, Karin
    Picard, Franck
    Emotte, Corinne
    Kobalava, Zhanna
    Moiseev, Valentin
    Schmouder, Robert
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2015, 53 (10) : 847 - 854
  • [7] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study
    Shakeri-Nejad, Kasra
    Aslanis, Vassilios
    Veldandi, Uday Kiran
    Gardin, Anne
    Zaehringer, Andreas
    Dodman, Angela
    Su, Zhenzhong
    Legangneux, Eric
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 41 - 53
  • [8] Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study
    Kasichayanula, Sreeneeranj
    Liu, Xiaoni
    Zhang, Weijiang
    Pfister, Marc
    LaCreta, Frank P.
    Boulton, David W.
    [J]. CLINICAL THERAPEUTICS, 2011, 33 (11) : 1798 - 1808
  • [9] Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study
    Chattopadhyay, Niladri
    Riecke, Kai
    Ligges, Sandra
    Zimmermann, Torsten
    Halabi, Atef
    Schultze-Mosgau, Marcus-Hillert
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 2011 - 2021
  • [10] Effects of Hepatic Impairment on the Pharmacokinetics of Everolimus: A Single-Dose, Open-Label, Parallel-Group Study
    Peveling-Oberhag, Jan
    Zeuzem, Stefan
    Yong, Wei Peng
    Kunz, Tiffany
    Paquet, Thierry
    Bouillaud, Emmanuel
    Urva, Shweta
    Anak, Oezlem
    Sellami, Dalila
    Kobalava, Zhanna
    [J]. CLINICAL THERAPEUTICS, 2013, 35 (03) : 215 - 225
12345